Publications by authors named "V Sandecka"

Claim this Profile
P
Precision medicine in hemato-oncology - treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/ MEK inhibitors.
M Štork, J Kotašková, E Ondroušková, M Borský, A Marečková

Klin Onkol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The treatment combination of obinutuzumab, bendamustine and dexamethasone achieved a deeper response than the previous line of treatment in five patients with Waldenström's macroglobulinemia.
Z Adam, L Pour, M Krejčí, V Sandecká, M Štork

Klin Onkol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of relapsed Waldenström's macroglobulinemia with proteasome inhibitors (bortezomib and subsequently ixazomib) in combination with rituximab and dexamethasone. A case report and review of the of proteasome inhibitors in Waldenström's….
Z Adam, M Krejčí, L Pour, B Weinbergerová, V Sandecká

Klin Onkol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab-exposed relapsed/refractory multiple myeloma patients: A retrospective analysis.
Dominik Fric, Martin Stork, Ivanna Boichuk, Viera Sandecka, Zdenek Adam

Eur J Haematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.
Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Viera Sandecka

Blood Cancer J· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis